Torasemide for the treatment of heart failure

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 2, 2008, Pages 127-132

  Ishido, Hirotaka ^a   Senzaki, Hideaki ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Diuretics; Furosemide; Heart failure; Torasemide

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LOOP DIURETIC AGENT; SPIRONOLACTONE; TORASEMIDE; DIURETIC AGENT; SULFONAMIDE;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURETIC ACTIVITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EXERCISE TOLERANCE; FATIGUE; FOOD; FOOD DRUG INTERACTION; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERURICEMIA; MORTALITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; QUALITY OF LIFE; RISK FACTOR; SINGLE DRUG DOSE; VASODILATATION; ANIMAL; COMPARATIVE STUDY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIURETICS; FUROSEMIDE; HEART FAILURE; HUMANS; QUALITY OF LIFE; SULFONAMIDES;

EID: 48249124218     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908784533685     Document Type: Article

References (59)

1. Packer, M.; Cohn, J.N. Consensus recommendations for the management of chronic heart failure. Am J. Cardiol, 1999,83,1A-38A.
2. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart. J., 2005, 26, 1115-40.
3. Hunt, S.A.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol., 2005, 46, e1-82.
4. Wittner, M.; Di Stefano, A.; Schlatter, E.; Delarge, J.; Greger, R., Torasemide inhibits NaCl reabsorption in the thick ascending limb of the loop of Henle. Pflugers Arch., 1986, 407, 611-4.
5. Sogame, Y.; Okano, K.; Hayashi, K.; Uchida, T.; Tsuda, Y. Urinary excretion profile of torasemide and its diuretic action in dogs. J. Pharm. Pharmacol., 1996, 48, 375-9.
6. Lee, D.Y.; Kim, J.Y.; Kim, Y.C.; Kwon, J.W.; Kim, W.B.; Lee, M.G. Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. Biopharm. Drug Dispos., 2005, 26, 173-82.
7. Barr, W.H.; Smith, H.L.; Karnes, H.T.; Brater, D.C. Torasemide dose-independent-proportionality of pharmacokinetics and pharmacodynamics. Prog. Pharmacol. Clin. Pharmacol., 1990, 8, 9-37.
8. Lesne, M. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittelforschung, 1988, 38, 160-3.
9. Neugebauer, G.; Besenfelder, E.; von Mollendorff, E. Pharmacokinetics and metabolism of torasemide in man. Arzneimittelforschung, 1988, 38, 164-6.
10. Blose, J.S.; Adams, K.F. Jr, Patterson, J.H. Shokujino eikyou. Torasemide: a pyridine-sulfonylurea loop diuretic. Ann. Pharmacother., 1995, 29, 396-402.
11. Dodion, L.; Ambroes, Y.; Lameire, N. A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers. Eur. J. Clin. Pharmacol., 1986, 31, 21-7.
12. Herchuelz, A. Comparative pharmacodynamics of torasemide and furosemide in patients with oedema. Arzneimittelforschung, 1988, 38, 180-3.
13. Broekhuysen, J.; Deger, F.; Douchamps, J.; Ducarne, H.; Herchuelz, A. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur. J. Clin. Pharmacol.. 1986, 31, 29-34.
14. Brater, D.C.; Day, B.; Burdette, A.; Anderson, S. Bumetanide and furosemide in heart failure. Kidney Int.. 1984, 26, 183-9.
15. Greither, A, Goldman, S, Edelen, JS, Benet, LZ, Cohn, K. Pharmacokinetics of furosemide in patients with congestive heart failure. Pharmacology, 1979, 19, 121-31.
16. Vasko, M.R.; Brater, D.C. Furosemide absorption altered in decompensated congestive heart failure. Ann. Intern. Med. 1985, 102, 314-8.
17. Vargo, D.; Kramer, W.G.; Black, P.K.; Smith, W.B.; Serpas, T.; Brater, D.C. The pharmacodynamics of torasemide in patients with congestive heart failure. Clin. Pharmacol. Ther., 1994, 56, 48-54.
18. Bleske, B.E.; Welage, L.S.; Kramer, W.G.; Nicklas, J.M. Pharmacokinetics of torasemide in patients with decompensated and compensated congestive heart failure. J. Clin. Pharmacol., 1998, 38, 708-14.
19. Uchida, T.; Yamanaga, K.; Nishikawa, M.; Ohtaki, Y.; Kido, H.; Watanabe. M. Anti-aldosteronergic effect of torasemide. Eur. J. Pharmacol., 1991, 205, 145-50.
20. Scoot, B.A.; Lawrence, B.; Nguyen, H.H.; Meyer, W.J. Aldosterone and dexamethasone binding in human arterial smooth muscle cells. J. Hypertens.. 1987, 5, 739-744.
21. Lombes, M.; Alfaidy, N.; Eugene, E.; Lessana, A.; Farman, N.; Bonvalet, J.P. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart. Circulation, 1995, 92, 175-82.
22. Zennaro, M.C.; Farman, N.; Bonbalet, J.P.; Lombes, M. Tissue-specific expression of α- and β-messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states. J. Clin. Endocrinol. Metab., 1997, 82, 1345-52.
23. Young, M.; Fullerton, M.; Dilley, R.; Funder, J.W. Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest., 1994, 92, 2578-83.
24. Brilla, C.G.; Zhou, G.; Matsubara, L.; Weber, K.T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J. Mol. Cell. Cardiol.. 1994, 26, 809-20.
25. Lombes, M.; Oblin, M.E, Gasc, J.M.; Baulieu, E.E.; Farman, N.; Bonvalet, J.P. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ. Res., 1992, 71, 503-10.
26. Robert, V.; Silvestre, J.S.; Charlemagne, D. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension, 1995, 26, 971-8.
27. Tsutamoto, T, Sakai, H, Wada, A, Ishikawa, C, Ohno, K, Fujii, M, Yamamoto, T, Takayama, T.; Dohke, T.; Horie, M. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J. Am. Coll. Cardiol., 2004, 44, 2252-3.
28. Tsutamoto, T.; Wada, A.; Maeda, K.; Mabuchi, N.; Hayashi, M.; Tsutsui, T.; Ohnishi, M.; Sawaki, M.; Fujii, M.; Matsumoto, T.; et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J. Am. Coll, Cardiol., 2000, 36, 838-44.
29. Goodfriend, T.L.; Ball, D.L.; Oelkers, W.; Bahr, V. Torasemide inhibits aldosterone secretion in vitro. Life. Sci., 1998, 63, 45-50.
30. Wilcox, C.S. Diuretics. In: Brenner BM. Brenner & Rector's The Kidney. (6th ed). Philadelphia. Saunders., 2000, pp2219-52.
31. Kim, G.H.; Masilamani, S.; Turner, R.; Mitchel, C.; Wade, J.B.; Knepper, M.A. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc. Natl. Acad. Sci. USA, 1998, 95, 14552-7.
32. Abdallah, J.G.; Schrier, R.W.; Edelstein, C.; Jennings, S.D.; Wyse, B.; Ellison, D.H. Loop diuretic infusion increases thiazide-sensitive Na(+)/ Cl(-)-cotransporter abundance: role of aldosterone. J. Am. Soc. Nephrol., 2001, 12, 1335-41.
33. Dupont, A.G.; Schoors, D.; Six, R.O.; Vanhaelst, L. Antihypertensive efficacy of low dose torasemide in essential hypertenssion: a placebo-controlled study. J. Hum. Hypertens., 1988, 2, 265-8.
34. Luft, F.C. Torasemide in the treatment of arterial hypertension. J. Cardiovasc. Pharmacol., 1993;, 22, S32-9.
35. Liguori, A, Casini, A.; Di Loreto, M.; Andreini, I.; Napoli, C. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur. J. Clin. Pharmacol. 1999, 55, 117-24.
36. de Berrazueta, J.R.; Gonzalez, J.P.; de Mier, I.; Poveda, J.J.; Garcia-Unzueta, M.T. Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. J. Cardiovasc. Pharmacol., 2007, 49, 90-5.
37. Yamanaga, K.; Uchida, T.; Kido, H.; Hayashi, K.; Watanabe, M. Torasemide, but not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J. Pharm. Pharmacol., 1992, 44, 64-5.
38. Fortuno, A.; Muniz, P.; Ravassa, S.; Rodriguez, J.A.; Fortuno, MA.; Zalba, G.; Diez, J. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension, 1999, 34, 138-43.
39. Fortuno, A.; Muniz, P.; Zalba, G.; Fortuno, M.A.; Diez, J. The loop diuretic torasemide interferes with endothelin-1 actions in the aorta of hypertensive rats. Nephrol. Dial. Transplant., 2001, 16, 18-21.
40. Senzaki, H.; Masutani, S.; Taketazu, M.; Kobayashi, J.; Kobayashi. T.; Sasaki, N.; Asano, H.; Kyo, S.; Yokote, Y. Assessment of cardiovascular dynamics by pressure-area relations in pediatric patients with congenital heart disease. J. Thoracic. Cardiovasc. Surg., 2001, 22, 535-47.
41. Achhammer, I.; Hacker, W.; Glocke, M. Efficacy and safety of torasemide in patients with chronic heart failure. Arzneimittelforschung, 1988, 38, 184-7.
42. Rogers, A.E.; Addington-Hall, J.M.; Abery, A.J.; McCoy, A.S.; Bulpitt, C.; Coats, A.J.; Gibbs, J.S. A qualitative study of chronic heart failure patients' understanding of their symptoms and drug therapy. Eur. J. Heart Fail., 2002, 4, 283-7.
43. Muller, K.; Gamba, G.; Jaquet, F.; Hess, B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life. Eur. J. Heart Fail., 2003, 5, 793-801.
44. Spannheimer, A.; Goertz, A.; Dreckmann-Behrendt, B. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int. J. Clin. Pract.. 1998, 52, 467-71.
45. Murray, M.D.; Deer, M.M.; Ferguson, J.A.; Dexter, P.R.; Bennett S.J.; Perkins, S.M.; Smith, F.E.; Lane, K.A.; Adams, L.D.; Tierney W.M.; Brater, D.C. Open-label randomized trial of torasemide compared with furosemide therapy for patients with heart failure. Am. J. Med., 2001, 111, 513-20.
46. Cosin, J.; Diez, J. TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail., 2002, 4, 507-13.
47. Pitt, B.; Zannad, F.; Remme, W.J.; Cody, R.; Castaigne, A.; Perez A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med., 1999, 341, 709-17.
48. Pitt, B. The role of aldosterone blockade in patients with heart failure. Heart Fail. Rev., 2005, 10, 79-83.
49. Kasama, S.; Toyama, T.; Hatori, T.; Sumino, H.; Kumakura, H. Takayama, Y.; Ichikawa, S.; Suzuki, T.; Kurabayashi, M. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart, 2006, 92, 1434-40.
50. Weber, K.T.; Brilla, C.G, Janicki, J.S. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc. Res., 1993, 27, 341-8.
51. Senzaki, H.; Gluzband, A.; Crow, M.T.; Kass, D.A. β-adrenergic blockade prevents MMP activation and diastolic dysfunction in short-term tachycardia-induced cardiodepression with angiotensin II. Circ. Res., 2000, 86, 807-15.
52. Delcayre, C.; Swynghedauw, B. Molecular mechanisms of myocardial remodeling: The role of aldosterone. J. Mol. Cell. Cardiol., 2002, 34, 1577-84.
53. Weber, K.T.; Gerling, I.C.; Kiani, M.F. Aldosteronism in heart failure: A proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr. Drug Targets, 2003, 4, 505-16.
54. Zannad, F.; Alla, F.; Douaset, B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation, 2000, 102, 2700-6.
55. Hayashi, M.; Tsutamoto, T.; Wada, A.. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation, 2003, 107, 2259-65.
56. Lopez, B.; Querejeta, R.; Gonzalez, A.; Sanchez, E.; Larman, M.; Diez, J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol., 2004, 43, 2028-35.
57. Yamato, M.; Sasaki, T.; Honda, K.; Fukuda, M.; Akutagawa, O.; Okamoto, M.; Hayashi, T. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J., 2003, 67, 384-90.
58. Naganuma, F.; Tsunoda, K, Koizumi, A.; Akuzawa, N.; Tsuchio, Y.; Kamiyama, H.; Suzuki, T.; Kurabayashi, M. Torasemide improves exercise tolerance and reduces heart rate in daily exercise more than furosemide in patients with chronic congestive heart failure. Jpn. J. Clin. Physiol., 2005, 35, 327-36.
59. Brater, D.C. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf., 1996, 14, 104-20.